Binghe Xu

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 40

Top Topics

Locally Advanced

Prognostic Factors

Top Venues

International journal of cancer

Journal of personalized medicine

Breast cancer research and treatment

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shu-Sen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai-Min Hui, Binghe Xu
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial. Nature communications 15 (1) (2024)
Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis. BMC cancer 24 (1) (2024)
Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis. BMC cancer 24 (1) (2024)
Aditya Bardia, Komal L Jhaveri, Seock-Ah Im, Sonia Pernas, Michelino De Laurentiis, Shu-Sen Wang, Noelia Martínez Jañez, Giuliano Borges, David W Cescon, Masaya Hattori, Yen-Shen Lu, Erika Paige Hamilton, Qingyuan Zhang, Junji Tsurutani, Kevin M Kalinsky, Pedro Emanuel Rubini Liedke, Lu Xu, Rick M Fairhurst, Sabrina Khan, Neelima Denduluri, Hope S Rugo, Binghe Xu, Barbara Pistilli, null null
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Mingxia Jiang, Yue Chai, Jiaxuan Liu, Maiyue He, Yipeng Wang, Xue Yang, Zeyu Xing, Mengqi Zhang, Shihan Zhou, Fei Ma, Jiayu Wang, Peng Yuan, Binghe Xu, Qiao Li
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis. BMC cancer 24 (1) (2024)
Sarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp, Funda Meric-Bernstam, David S Hong, Jordi A Rodon, Apostolia M Tsimberidou, Kanwal Raghav, Jaffer A Ajani, Anthony P Conley, Frank Mott, Ying Fan, Jean Fan, Peng Peng, Hui Wang, Shumao Ni, Caixia Sun, Xiaoyan Qiang, Wendy J Levin, Brenda Ngo, Qinhua Cindy Ru, Frank Wu, Milind M Javle
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. The oncologist 29 (4) (2024)
Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shu-Sen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai-Min Hui, Binghe Xu
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial. Nature communications 15 (1) (2024)
Hongnan Mo, Yongpei Yu, Xiaoying Sun, Hewei Ge, Lanlan Yu, Xiuwen Guan, Jingtong Zhai, Aihua Zhu, Yuhan Wei, Jinjing Wang, Xiaoyan Yan, Hai-Li Qian, Binghe Xu, Zongbi Yi
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nature medicine (2024)
Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shu-Sen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai-Min Hui, Binghe Xu
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial. Nature communications 15 (1) (2024)
Sarina A Piha-Paul, Binghe Xu, Ecaterina E Dumbrava, Siqing Fu, Daniel D Karp, Funda Meric-Bernstam, David S Hong, Jordi A Rodon, Apostolia M Tsimberidou, Kanwal Raghav, Jaffer A Ajani, Anthony P Conley, Frank Mott, Ying Fan, Jean Fan, Peng Peng, Hui Wang, Shumao Ni, Caixia Sun, Xiaoyan Qiang, Wendy J Levin, Brenda Ngo, Qinhua Cindy Ru, Frank Wu, Milind M Javle
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors. The oncologist (2024)
Qi Zhao, Mingxia Jiang, Jiaxuan Liu, Mengqi Zhang, Maiyue He, Shihan Zhou, Jiani Wang, Hongnan Mo, Bo Lan, Peng Yuan, Pin Zhang, Fei Ma, Qiao Li, Binghe Xu
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancer. Cancer biology & medicine (2024)
Zhijun Li, Yi-Qun Han, Jiayu Wang, Binghe Xu
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy. Journal of personalized medicine 13 (2) (2023)
Fei Ma, Min Yan, Wei Li, Quchang Ouyang, Zhongsheng Tong, Yuee Teng, Yongsheng Wang, Shusen Wang, Cuizhi Geng, Ting Luo, Jincai Zhong, Qingyuan Zhang, Qiang Liu, Xiaohua Zeng, Tao Sun, Qinguo Mo, Hu Liu, Ying Cheng, Jing Cheng, Xiaojia Wang, Jianyun Nie, Jin Yang, Xinhong Wu, Xinshuai Wang, Huiping Li, Changsheng Ye, Fangli Dong, Shuchao Wu, Xiaoyu Zhu, Binghe Xu, null null
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. BMJ (Clinical research ed.) 383 (2023)
Yiqun Han, Jiayu Wang, Binghe Xu
Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer. Journal of personalized medicine 13 (3) (2023)
Junning Cao, Hongqian Guo, Dongmei Ji, Weina Shen, Shun Zhang, Chih-Yi Hsieh, Sui Xiong Cai, Ye Edward Tian, Cong Xu, Pin Zhang, Binghe Xu
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial. The oncologist (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer 152 (10) (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer (2023)
Yang Luo, Ying Cheng, Chunjiao Wu, Hui Ye, Naihan Chen, Fan Zhang, Hua Wei, Binghe Xu
Pharmacokinetics, safety, and antitumor activity of talazoparib monotherapy in Chinese patients with advanced solid tumors. Investigational new drugs (2023)
Zhijun Li, Yi-Qun Han, Jiayu Wang, Binghe Xu
Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy. Journal of personalized medicine 13 (2) (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer (2023)
Mingxia Jiang, Jiaxuan Liu, Qiao Li, Binghe Xu
The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status. International journal of cancer (2023)
Jiaxuan Liu, Maiyue He, Kaiping Ou, Xin Wang, Yipeng Wang, Liqiang Qi, Yue Chai, Mingxia Jiang, Zongbi Yi, Yang Luo, Peng Yuan, Pin Zhang, Binghe Xu, Qiao Li
Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis. International journal of cancer (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer 152 (10) (2023)
Yiqun Han, Jiayu Wang, Binghe Xu
Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer. Journal of personalized medicine 13 (3) (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer 152 (10) (2023)
Fengzhu Guo, Jialu Ma, Cong Li, Shuning Liu, Weizheng Wu, Chunxiao Li, Jiani Wang, Jinsong Wang, Zhijun Li, Jingtong Zhai, Fangzhou Sun, Yantong Zhou, Changyuan Guo, Hai-Li Qian, Binghe Xu
PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer. Cell death & disease 14 (4) (2023)
Yiqun Han, Jiayu Wang, Binghe Xu
Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer. Journal of personalized medicine 13 (3) (2023)
Yiqun Li, Zhongsheng Tong, Xinhong Wu, Quchang Ouyang, Li Cai, Wei Li, Zhiyong Yu, Zhengxiang Han, Xiaojia Wang, Man Li, Haibo Wang, Li Li, Jin Yang, Zhaofeng Niu, Qitang Wang, Binghe Xu
Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study. International journal of cancer (2023)
Binghe Xu, Fei Ma, Tao Wang, Shu-Sen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. International journal of cancer 152 (10) (2023)
Fengzhu Guo, Cong Li, Shuning Liu, Zhijun Li, Jingtong Zhai, Zhiwu Wang, Binghe Xu
High BRCA1 expression is an independent prognostic biomarker in LUAD and correlates with immune infiltration. Cancer innovation 2 (2) (2023)
Binghe Xu, Tao Sun, Yanxia Shi, Jiuwei Cui, Yongmei Yin, Quchang Ouyang, Qiang Liu, Qingyuan Zhang, Yiding Chen, Shouman Wang, Xiaojia Wang, Zhongsheng Tong, Yahua Zhong, Jiayu Wang, Min Yan, Xi Yan, Chuan Wang, Jifeng Feng, Xiuli Wang, Gang Hu, Ying Cheng, Ruimin Ge, Zhaoyin Zhu, Wa Zhang, Zhimin Shao
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study. Breast cancer research and treatment (2022)
Jiani Wang, Yi-Qun Han, Jiayu Wang, Qing Li, Binghe Xu
Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis. Cancers 14 (24) (2022)
Binghe Xu, Wei Li, Qingyuan Zhang, Qiao Li, Xiaojia Wang, Huiping Li, Tao Sun, Yongmei Yin, Hong Zheng, Jifeng Feng, Huaqi Zhu, Asna Siddiqui, Harrison Macharia, Adam Knott
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study. Breast cancer research and treatment (2022)
Ruoxi Hong, Binghe Xu
Breast cancer: an up-to-date review and future perspectives. Cancer communications (London, England) 42 (10) (2022)
Jiani Wang, Yi-Qun Han, Jiayu Wang, Qing Li, Binghe Xu
Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis. Cancers 14 (24) (2022)
Binghe Xu, Qingyuan Zhang, Pin Zhang, Xichun Hu, Wei Li, Zhongsheng Tong, Tao Sun, Yuee Teng, Xinhong Wu, Quchang Ouyang, Xi Yan, Jing Cheng, Qiang Liu, Jifeng Feng, Xiaojia Wang, Yongmei Yin, Yanxia Shi, Yueyin Pan, Yongsheng Wang, Weimin Xie, Min Yan, Yunjiang Liu, Ping Yan, Fei Wu, Xiaoyu Zhu, Jianjun Zou, null null
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nature medicine 27 (11) (2021)
Binghe Xu, Wei Li, Qingyuan Zhang, Zhimin Shao, Qiao Li, Xiaojia Wang, Huiping Li, Tao Sun, Yongmei Yin, Hong Zheng, Jifeng Feng, Hong Zhang, Guiyuan Lei, Eleonora Restuccia
Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast cancer research and treatment 182 (3) (2020)
Jiayu Wang, Weiwei Li, Yujian Shi, Yan Huang, Tao Sun, Lili Tang, Qing Lu, Qiumo Lei, Ning Liao, Feng Jin, Hui Li, Tao Huang, Jun Qian, Danmei Pang, Shusen Wang, Peizhi Fan, Xinhong Wu, Ying Lin, Haiyan Qin, Binghe Xu
Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes. Cancer medicine 8 (5) (2019)
Jiayu Wang, Binghe Xu, Wenna Wang, Xiaoyu Zhai, Xuelian Chen
Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis. Breast cancer research and treatment 171 (3) (2018)
Wenjie Zhu, Mei Liu, Ying Fan, Fei Ma, Ningzhi Xu, Binghe Xu
Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. Cancer medicine 7 (9) (2018)